Anti-inflammatory activity of a pteridine derivative (4AZA2096) alleviates TNBS-induced colitis in mice

Journal of Interferon and Cytokine Research

Volumn 26, Issue 8, 2006, Pages 575-582

  Shen, Chong ^a   Dillissen, Ellen ^a   Kasran, Ahmad ^a   Lin, Yuan ^b   Clydesdale, Gavin ^b   Sienaert, Ilse ^b   De Jonghe, Steven ^b   Gao, Ling Jie ^b   Geboes, Karel ^c   Boon, Louis ^b   Rutgeerts, Paul ^c   Ceuppens, Jan L ^a,d  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b 4AZA Biosciences ^*  (Belgium)

^c Faculty of Medicine   (Belgium)

^d Experimental Laboratory Immunology   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4AZA2096; CYTOKINE RECEPTOR ANTAGONIST; MYELOPEROXIDASE; PTERIDINE DERIVATIVE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; COLITIS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG INDUCED DISEASE; EDEMA; ENZYME ACTIVITY; GOBLET CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES; CELLS, CULTURED; COLITIS; COLON; CYTOKINES; HUMANS; INTERLEUKIN-1; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; PEROXIDASE; PTERIDINES; RNA, MESSENGER; T-LYMPHOCYTES; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 33747884942     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.26.575     Document Type: Article

References (32)

1. Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger R, Yim JJ, Wachter H. Biochemistry and function of pteridine synthesis in human and murine macrophages. Pathobiology 1991;59:276-279.
2. Wirleitner B, Reider D, Ebner S, Bock G, Widner B, Jaeger M, Schennach H, Romani N, Fuchs D. Monocyte-derived dendritic cells release neopterin. J. Leukoc. Biol. 2002;72:1148-1153.
3. Barak M, Gruener N. Neopterin augmentation of tumor necrosis factor production. Immunol. Lett. 1991;30:101-106.
4. Brandacher G, Zou Y, Obrist P, Steurer W, Werner-Felmayer G, Margreiter R, Werner ER. The 4-amino analogue of tetrahydrobiopterin efficiently prolongs murine cardiac-allograft survival. J. Heart Lung Transplant. 2001;20:747-749.
5. Ziegler I, Schwulera U. Modulation of interleukin 2 high-affinity binding by lymphocyte-derived tetrahydrobiopterin: pterins as potential participants in the control of interleukin 2 receptor assembly. J. Cell. Biochem. 1989;41:103-112.
6. Bahrami S, Fitzal F, Peichl G, Gasser H, Fuerst W, Banerjee A, Strohmaier W, Redl H, Werner-Felmayer G, Werner ER. Protection against endotoxemia in rats by a novel tetrahydrobiopterin analogue. Shock 2000;13:386-391.
7. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803.
8. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 2002;20:495-549.
9. Waer M, Vanrenterghem Y, Van der Schueren E, Michielsen P, Vandeputte M. Identification and function of a major OKT3, OKT8, Leu-7, positive lymphocyte subpopulation in renal transplant recipients treated with total lymphoid irradiation. Transplant. Proc. 1987;19:1570-1571.
10. Shen C, Bullens D, Kasran A, Maerten P, Boon L, Aerts JM, Van Assche G, Geboes K, Rutgeerts P, Ceuppens JL. Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis. Int. Immunopharmacol. 2004;4:939-951.
11. Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Buschenfelde KH, Strober W, Kollias G. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. J. Immunol. 1997;27:1743-1750,
12. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-448.
13. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker-Smith JA, MacDonald TT. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-1466.
14. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999;10:387-398.
15. McHale JF, Harari OA, Marshall D, Harari OA, Marshall D, Haskard DO. Vascular endothelial cell expression of ICAM-1 and VCAM-1 at the onset of eliciting contact hypersensitivity in mice: evidence for a dominant role of TNF-alpha. J. Immunol. 1999;162:1648-1655.
16. Stocker CJ, Sugars KL, Harari OA, Landis RC, Morley BJ, Haskard DO. TNF-alpha, IL-4, and IFN-gamma regulate differential expression of P- and E-selectin expression by porcine aortic endothelial cells. J. Immunol. 2000;164:3309-3315.
17. Swallow MM, Wallin JJ, Sha WC. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity 1999;11:423-432.
18. Sedgwick JD, Riminton DS, Cyster JG, Korner H. Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol. Today 2000;21:110-113.
19. Maiti A, Maki G, Johnson P. TNF-alpha induction of CD44-mediated leukocyte adhesion by sulfation. Science 1998;282:941-943.
20. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
21. Shibuya K, Robinson D, Zonin F, Hartley SB, Macatonia SE, Somoza C, Hunter CA, Murphy KM, O'Garra A. IL-1 alpha and TNF-alpha are required for IL-12-induced development of Th1 cells producing high levels of IFN-gamma in BALB/c but not C57BL/6 mice. J. Immunol. 1998;160:1708-1716.
22. Lahn M, Kalataradi H, Mittelstadt P, Pflum E, Vollmer M, Cady C, Mukasa A, Vella AT, Ikle D, Harbeck R, O'Brien R, Born W. Early preferential stimulation of gamma delta T cells by TNF-alpha. J. Immunol. 1998;160:5221-5230.
23. Becher B, Blain M, Giacomini PS, Antel JP. Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen-presenting cell-derived IL-12. J. Immunol. 1999;162:684-688.
24. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kronke M, Mak TW. Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-467.
25. Rudin W, Eugster HP, Bordmann G, Bonato J, Muller M, Yamage M, Ryffel B. Resistance to cerebral malaria in tumor necrosis factor-α/β-deficient mice is associated with a reduction of intercellular adhesion molecule-1 up-regulation and T helper type 1 response. Am. J. Pathol. 1997;150:257-266.
26. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, Targan SR. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J. Immunol. 1997;159:6276-6282.
27. Prehn JL, Landers CJ, Targan SR. A soluble factor produced by lamina propria mononuclear cells is required for TNF-alpha enhancement of IFN-gamma production by T cells. J. Immunol. 1999;163:4277-4283.
28. Kunkel EJ, Plavec I, Nguyen D, Melrose J, Rosler ES, Kao LT, Wang Y, Hytopoulos E, Bishop AC, Bateman R, Shokat KM, Butcher EC, Berg EL. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay Drug Dev. Technol. 2004;2:431-441.
29. Butcher RA, Schreiber SL. Using genome-wide transcriptional profiling to elucidate small-molecule mechanism. Curr. Opin. Chem. Biol. 2005;9:25-30.
30. Drews J. Stategic trends in the drug industry. Drug Discov. Today 2003;8:411-420.
31. Williams M. Target validation. Curr. Opin. Pharmacol. 2003;3:571-577.
32. Kubinyi H. Drug research: myths, hype and reality. Natl. Rev. Drug. Discov. 2003;2:665-668.